A short read on in vivo base editing. The baby in Pennsylvania who got a one-of-one medicine, how the pencil replaced the scissors, the fat bubble that smuggles editors into the liver, and why this may be the most consequential drug-class shift since the antibody.

A short read on GLP-1 drugs (Ozempic, Mounjaro, Wegovy, Zepbound). The lizard-venom origin, how chemists rebuilt the hormone to last a week, the trillion-dollar Lilly/Novo race, and the asymmetric bets on longevity, addiction, cancer, and brain disease.

A short read on Yamanaka factors and cellular reprogramming. The contrarian idea that aging is corrupted information, how four proteins rewind a cell, the four-billion-dollar race to commercialize it, and what real success would look like.